Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib
Hélène Labussière(Hôpital Lyon Sud), Franck E. Nicolini(Université Claude Bernard Lyon 1), Joëlle Bernard(Hôpital Edouard Herriot), Mauricette Michallet(Université Claude Bernard Lyon 1), Isabelle Tigaud(Inserm), Kaddour Chabane(Hospices Civils de Lyon), Marie‐Claude Gagnieu(Hôpital Edouard Herriot), Jean‐Pierre Magaud(Hôpital Lyon Sud), Sandrine Hayette(Hôpital Claude Huriez), Quoc‐Hung Le(Hôpital Edouard Herriot), Fiorenza Barraco(Hôpital Lyon Sud)
Cited by 11
Related Papers
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431